留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

氨柔比星用于小细胞肺癌二线治疗的荟萃分析

靳海潮,  邢方凯,  陈涛,  吕文苓

downloadPDF
文章导航 > 药学实践与服务  > 2017 >  35(1): 82-86
靳海潮, 邢方凯, 陈涛, 吕文苓. 氨柔比星用于小细胞肺癌二线治疗的荟萃分析[J]. 药学实践与服务, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
引用本文: 靳海潮, 邢方凯, 陈涛, 吕文苓. 氨柔比星用于小细胞肺癌二线治疗的荟萃分析[J]. 药学实践与服务, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
shu
JIN Haichao, XING Fangkai, CHEN Tao, LV Wenling. Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
Citation: JIN Haichao, XING Fangkai, CHEN Tao, LV Wenling. Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
shu

氨柔比星用于小细胞肺癌二线治疗的荟萃分析

doi: 10.3969/j.issn.1006-0111.2017.01.021
  • 1.

    烟台71571部队, 山东 烟台 265500

  • 2.

    烟台毓璜顶医院妇产科, 山东 烟台 265000

Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis

  • 1.

    The 71571 Unit of PLA, Yantai 265500, China

  • 2.

    The Gynecology & Obstetrics of Yuhuangding Hospital, Yantai 265000, China

  • 摘要: 目的 系统评价氨柔比星治疗小细胞肺癌（small-cell lung cancer， SCLC）的疗效及安全性。 方法 检索PubMed、EMBASE、CNKI及The Cochrane Library等数据库，收集有关氨柔比星治疗SCLC的研究；主要结局指标包括总有效率（overall response rate，ORR）、无进展生存率（progression free survival， PFS）、总生存率（overall survival， OS）及不良事件。 结果 共有6项研究纳入，荟萃分析（Meta分析）显示，氨柔比星应用于SCLC二线治疗时的总有效率显著高于对照组[RR 1.72，95% CI（1.39，2.14），P=0.000]，但总生存率[HR 0.93，95% CI（0.81，1.07），P=0.405]和无进展生存率[HR 0.98，95% CI（0.83，1.17），P=0.456]与对照组相比无明显差异。 结论 氨柔比星治疗SCLC的总有效率高于对照组，且PFS和OS与对照组相比无显著性差异（P=0.405，P=0.456），因此，氨柔比星可作为SCLC的二线治疗药物。
    Abstract: Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer(SCLC). Methods PubMed, Embase, the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC. A Meta-analysis was performed over the published clinical trials. The efficacy and safety of amrubicin were evaluated based on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity. Results Our analysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group[RR 1.72,95% CI (1.39, 2.14),P=0.000], the OS, PFS and toxicity were no-inferior to the control group(P=0.405,P=0.456). Conclusion Amrubicin can be considered as a good second-line treatment for relapsed SCLC.
  • [1] Cheng S, Evans WK, Stys-Norman D, et al. Chemotherapy for relapsed small cell lung cancer:a systematic review and practice guideline[J]. J Thorac Oncol, 2007,2(4):348-354.
    [2] Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC)[J]. Cancer Treat Rev, 2011,37(2):143-150.
    [3] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA, 2000,283(15):2008-2012.
    [4] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010,25(9):603-605.
    [5] O'Brien ME, Konopa K, Lorigan P, et al. Randomised phase Ⅱ study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer-EORTC 08062[J]. Eur J Cancer, 2011,47(15):2322-2330.
    [6] Satouchi M, Kotani Y, Shibata T, et al. Phase Ⅲ study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer:JCOG 0509[J]. J Clin Oncol, 2014,32(12):1262-1268.
    [7] Sekine I, Okamoto H, Horai T, et al. A randomized phase Ⅲ study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer[J]. Clin Lung Cancer, 2014,15(2):96-102.
    [8] Wakuda K, Kenmotsu H, Naito T, et al. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer[J]. Am J Clin Oncol, 2015,38(1):28-32.
    [9] Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase Ⅱ trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer:North Japan Lung Cancer Study Group Trial 0402[J]. J Clin Oncol, 2008,26(33):5401-5406.
    [10] Inoue A, Sugawara S, Maemondo M, et al. Randomized phase Ⅱ trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer:North Japan Lung Cancer Study Group trial 0702[J]. Lung Cancer, 2015, 89(1):61-65.
    [11] Jotte R, Conkling P, Reynolds C, et al. Randomized phase Ⅱ trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy[J]. J Clin Oncol, 2011,29(3):287-293.
    [12] von Pawel J, Jotte R, Spigel DR, et al. Randomized phase Ⅲ trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer[J]. J Clin Oncol, 2014,32(35):4012-4019.
    [13] Tani N, Yabuki M, Komuro S, et al. Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride[J]. Xenobiotica, 2005,35(12):1121-1133.
  • [1] 迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛.  负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
    [2] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
    [3] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
    [4] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
    [5] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [6] 刘汝雄, 杨万镇, 涂杰, 盛春泉.  铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
    [7] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [8] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3199
  • HTML全文浏览量:  360
  • PDF下载量:  864
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-03-07
  • 修回日期:  2016-07-18

氨柔比星用于小细胞肺癌二线治疗的荟萃分析

doi: 10.3969/j.issn.1006-0111.2017.01.021
  • 1. 烟台71571部队, 山东 烟台 265500
  • 2. 烟台毓璜顶医院妇产科, 山东 烟台 265000
  • 收稿日期: 2016-03-07
  • 修回日期: 2016-07-18

摘要: 目的 系统评价氨柔比星治疗小细胞肺癌（small-cell lung cancer， SCLC）的疗效及安全性。 方法 检索PubMed、EMBASE、CNKI及The Cochrane Library等数据库，收集有关氨柔比星治疗SCLC的研究；主要结局指标包括总有效率（overall response rate，ORR）、无进展生存率（progression free survival， PFS）、总生存率（overall survival， OS）及不良事件。 结果 共有6项研究纳入，荟萃分析（Meta分析）显示，氨柔比星应用于SCLC二线治疗时的总有效率显著高于对照组[RR 1.72，95% CI（1.39，2.14），P=0.000]，但总生存率[HR 0.93，95% CI（0.81，1.07），P=0.405]和无进展生存率[HR 0.98，95% CI（0.83，1.17），P=0.456]与对照组相比无明显差异。 结论 氨柔比星治疗SCLC的总有效率高于对照组，且PFS和OS与对照组相比无显著性差异（P=0.405，P=0.456），因此，氨柔比星可作为SCLC的二线治疗药物。

English Abstract

靳海潮, 邢方凯, 陈涛, 吕文苓. 氨柔比星用于小细胞肺癌二线治疗的荟萃分析[J]. 药学实践与服务, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
引用本文: 靳海潮, 邢方凯, 陈涛, 吕文苓. 氨柔比星用于小细胞肺癌二线治疗的荟萃分析[J]. 药学实践与服务, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
shu
JIN Haichao, XING Fangkai, CHEN Tao, LV Wenling. Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
Citation: JIN Haichao, XING Fangkai, CHEN Tao, LV Wenling. Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
shu

    全文HTML

参考文献 (13)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计